Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection
Background/Aims: Curative resection is still the only treatment for patients with pancreatic ductal adenocarcinoma (PDAC). However, early postoperative recurrence occurs frequently. The aim of this study was to investigate the predictors of early recurrence of PDAC. Methods: Clinical data of 172 con...
Gespeichert in:
| Veröffentlicht in: | Digestive surgery 2017-01, Vol.34 (2), p.125-132 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 132 |
|---|---|
| container_issue | 2 |
| container_start_page | 125 |
| container_title | Digestive surgery |
| container_volume | 34 |
| creator | Hosokawa, Yuichi Nagakawa, Yuichi Sahara, Yatsuka Takishita, Chie Katsumata, Kenji Tsuchida, Akihiko |
| description | Background/Aims: Curative resection is still the only treatment for patients with pancreatic ductal adenocarcinoma (PDAC). However, early postoperative recurrence occurs frequently. The aim of this study was to investigate the predictors of early recurrence of PDAC. Methods: Clinical data of 172 consecutive patients with PDAC who underwent curative resection (R0) between 2000 and 2015 at Tokyo Medical University Hospital were retrospectively analyzed. Results: The median follow-up period was 18.2 months. Recurrence occurred in 96 of 172 (55.8%) patients, 27 in whom recurrence occurred within 6 months (early recurrence). Median survival time of the early recurrence group was 10.7 months. The optimal cutoff concentrations for the prediction of early recurrence were 111.3 U/ml, 3.0 ng/ml, 41 U/ml and 670 U/ml for CA19-9, carcinoembryonic antigen, SPan-1 and DUPAN-2, respectively. Multivariate analysis demonstrated that a SPan-1 concentration of >41 U/ml, having received neoadjuvant therapy and having never received adjuvant chemotherapy were significant and independent predictors of early recurrence. Conclusion: A preoperative SPan-1 concentration of >41 U/ml is a significant and independent predictor of the early recurrence of pancreatic adenocarcinoma. |
| doi_str_mv | 10.1159/000449041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859725545</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1859725545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-5e76c3c7e231a594a04eff34653bec1765574f51eda0741643a06756ad6c814f3</originalsourceid><addsrcrecordid>eNo90M9LwzAUB_AgipvTg3eRHPVQze-0RymbDgbKpueSZS8jrms1aYX990Y2d8hLCJ_3eHwRuqbkgVJZPBJChCiIoCdoSAWjWZHn_BQNCZM8E3muBugixs_EuCroORowrWTOGB2iegGh3-LFm2kyiqcRG7zw68Y7b03T4bmPGzwxtmsDdumMTah3eA62DwEaC7h1OLXaAKbzFpfpCQEb16Va9iF9_kDiEWzn2-YSnTlTR7g63CP0MRm_ly_Z7PV5Wj7NMss16zIJWlluNTBOjSyEIQKc40JJvgRL0-5SCycprAzRgirBDVFaKrNSNqfC8RG628_9Cu13D7Grtj5aqGvTQNvHiuay0ExKIRO931Mb2hgDuOor-K0Ju4qS6i_c6hhusreHsf1yC6uj_E8zgZs92JiwhnAEh_5fk7p7sg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1859725545</pqid></control><display><type>article</type><title>Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection</title><source>Karger Journals</source><source>MEDLINE</source><creator>Hosokawa, Yuichi ; Nagakawa, Yuichi ; Sahara, Yatsuka ; Takishita, Chie ; Katsumata, Kenji ; Tsuchida, Akihiko</creator><creatorcontrib>Hosokawa, Yuichi ; Nagakawa, Yuichi ; Sahara, Yatsuka ; Takishita, Chie ; Katsumata, Kenji ; Tsuchida, Akihiko</creatorcontrib><description>Background/Aims: Curative resection is still the only treatment for patients with pancreatic ductal adenocarcinoma (PDAC). However, early postoperative recurrence occurs frequently. The aim of this study was to investigate the predictors of early recurrence of PDAC. Methods: Clinical data of 172 consecutive patients with PDAC who underwent curative resection (R0) between 2000 and 2015 at Tokyo Medical University Hospital were retrospectively analyzed. Results: The median follow-up period was 18.2 months. Recurrence occurred in 96 of 172 (55.8%) patients, 27 in whom recurrence occurred within 6 months (early recurrence). Median survival time of the early recurrence group was 10.7 months. The optimal cutoff concentrations for the prediction of early recurrence were 111.3 U/ml, 3.0 ng/ml, 41 U/ml and 670 U/ml for CA19-9, carcinoembryonic antigen, SPan-1 and DUPAN-2, respectively. Multivariate analysis demonstrated that a SPan-1 concentration of >41 U/ml, having received neoadjuvant therapy and having never received adjuvant chemotherapy were significant and independent predictors of early recurrence. Conclusion: A preoperative SPan-1 concentration of >41 U/ml is a significant and independent predictor of the early recurrence of pancreatic adenocarcinoma.</description><identifier>ISSN: 0253-4886</identifier><identifier>EISSN: 1421-9883</identifier><identifier>DOI: 10.1159/000449041</identifier><identifier>PMID: 27658221</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Aged ; Antigens, Neoplasm - blood ; Area Under Curve ; CA-19-9 Antigen - blood ; Carcinoembryonic Antigen - blood ; Carcinoma, Pancreatic Ductal - blood ; Carcinoma, Pancreatic Ductal - secondary ; Carcinoma, Pancreatic Ductal - therapy ; Chemoradiotherapy, Adjuvant ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Drainage ; Female ; Follow-Up Studies ; Humans ; Jaundice, Obstructive - etiology ; Jaundice, Obstructive - surgery ; Liver Neoplasms - secondary ; Lung Neoplasms - secondary ; Lymphatic Metastasis ; Male ; Neoadjuvant Therapy ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnostic imaging ; Original Paper ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - therapy ; Peritoneal Neoplasms - secondary ; Predictive Value of Tests ; Preoperative Period ; Retrospective Studies ; Risk Factors ; ROC Curve ; Survival Rate ; Time Factors</subject><ispartof>Digestive surgery, 2017-01, Vol.34 (2), p.125-132</ispartof><rights>2016 S. Karger AG, Basel</rights><rights>2016 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-5e76c3c7e231a594a04eff34653bec1765574f51eda0741643a06756ad6c814f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27658221$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hosokawa, Yuichi</creatorcontrib><creatorcontrib>Nagakawa, Yuichi</creatorcontrib><creatorcontrib>Sahara, Yatsuka</creatorcontrib><creatorcontrib>Takishita, Chie</creatorcontrib><creatorcontrib>Katsumata, Kenji</creatorcontrib><creatorcontrib>Tsuchida, Akihiko</creatorcontrib><title>Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection</title><title>Digestive surgery</title><addtitle>Dig Surg</addtitle><description>Background/Aims: Curative resection is still the only treatment for patients with pancreatic ductal adenocarcinoma (PDAC). However, early postoperative recurrence occurs frequently. The aim of this study was to investigate the predictors of early recurrence of PDAC. Methods: Clinical data of 172 consecutive patients with PDAC who underwent curative resection (R0) between 2000 and 2015 at Tokyo Medical University Hospital were retrospectively analyzed. Results: The median follow-up period was 18.2 months. Recurrence occurred in 96 of 172 (55.8%) patients, 27 in whom recurrence occurred within 6 months (early recurrence). Median survival time of the early recurrence group was 10.7 months. The optimal cutoff concentrations for the prediction of early recurrence were 111.3 U/ml, 3.0 ng/ml, 41 U/ml and 670 U/ml for CA19-9, carcinoembryonic antigen, SPan-1 and DUPAN-2, respectively. Multivariate analysis demonstrated that a SPan-1 concentration of >41 U/ml, having received neoadjuvant therapy and having never received adjuvant chemotherapy were significant and independent predictors of early recurrence. Conclusion: A preoperative SPan-1 concentration of >41 U/ml is a significant and independent predictor of the early recurrence of pancreatic adenocarcinoma.</description><subject>Aged</subject><subject>Antigens, Neoplasm - blood</subject><subject>Area Under Curve</subject><subject>CA-19-9 Antigen - blood</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Carcinoma, Pancreatic Ductal - blood</subject><subject>Carcinoma, Pancreatic Ductal - secondary</subject><subject>Carcinoma, Pancreatic Ductal - therapy</subject><subject>Chemoradiotherapy, Adjuvant</subject><subject>Chemotherapy, Adjuvant</subject><subject>Disease-Free Survival</subject><subject>Drainage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Jaundice, Obstructive - etiology</subject><subject>Jaundice, Obstructive - surgery</subject><subject>Liver Neoplasms - secondary</subject><subject>Lung Neoplasms - secondary</subject><subject>Lymphatic Metastasis</subject><subject>Male</subject><subject>Neoadjuvant Therapy</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Original Paper</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Peritoneal Neoplasms - secondary</subject><subject>Predictive Value of Tests</subject><subject>Preoperative Period</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>ROC Curve</subject><subject>Survival Rate</subject><subject>Time Factors</subject><issn>0253-4886</issn><issn>1421-9883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90M9LwzAUB_AgipvTg3eRHPVQze-0RymbDgbKpueSZS8jrms1aYX990Y2d8hLCJ_3eHwRuqbkgVJZPBJChCiIoCdoSAWjWZHn_BQNCZM8E3muBugixs_EuCroORowrWTOGB2iegGh3-LFm2kyiqcRG7zw68Y7b03T4bmPGzwxtmsDdumMTah3eA62DwEaC7h1OLXaAKbzFpfpCQEb16Va9iF9_kDiEWzn2-YSnTlTR7g63CP0MRm_ly_Z7PV5Wj7NMss16zIJWlluNTBOjSyEIQKc40JJvgRL0-5SCycprAzRgirBDVFaKrNSNqfC8RG628_9Cu13D7Grtj5aqGvTQNvHiuay0ExKIRO931Mb2hgDuOor-K0Ju4qS6i_c6hhusreHsf1yC6uj_E8zgZs92JiwhnAEh_5fk7p7sg</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Hosokawa, Yuichi</creator><creator>Nagakawa, Yuichi</creator><creator>Sahara, Yatsuka</creator><creator>Takishita, Chie</creator><creator>Katsumata, Kenji</creator><creator>Tsuchida, Akihiko</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170101</creationdate><title>Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection</title><author>Hosokawa, Yuichi ; Nagakawa, Yuichi ; Sahara, Yatsuka ; Takishita, Chie ; Katsumata, Kenji ; Tsuchida, Akihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-5e76c3c7e231a594a04eff34653bec1765574f51eda0741643a06756ad6c814f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Antigens, Neoplasm - blood</topic><topic>Area Under Curve</topic><topic>CA-19-9 Antigen - blood</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Carcinoma, Pancreatic Ductal - blood</topic><topic>Carcinoma, Pancreatic Ductal - secondary</topic><topic>Carcinoma, Pancreatic Ductal - therapy</topic><topic>Chemoradiotherapy, Adjuvant</topic><topic>Chemotherapy, Adjuvant</topic><topic>Disease-Free Survival</topic><topic>Drainage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Jaundice, Obstructive - etiology</topic><topic>Jaundice, Obstructive - surgery</topic><topic>Liver Neoplasms - secondary</topic><topic>Lung Neoplasms - secondary</topic><topic>Lymphatic Metastasis</topic><topic>Male</topic><topic>Neoadjuvant Therapy</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Original Paper</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Peritoneal Neoplasms - secondary</topic><topic>Predictive Value of Tests</topic><topic>Preoperative Period</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>ROC Curve</topic><topic>Survival Rate</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hosokawa, Yuichi</creatorcontrib><creatorcontrib>Nagakawa, Yuichi</creatorcontrib><creatorcontrib>Sahara, Yatsuka</creatorcontrib><creatorcontrib>Takishita, Chie</creatorcontrib><creatorcontrib>Katsumata, Kenji</creatorcontrib><creatorcontrib>Tsuchida, Akihiko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hosokawa, Yuichi</au><au>Nagakawa, Yuichi</au><au>Sahara, Yatsuka</au><au>Takishita, Chie</au><au>Katsumata, Kenji</au><au>Tsuchida, Akihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection</atitle><jtitle>Digestive surgery</jtitle><addtitle>Dig Surg</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>34</volume><issue>2</issue><spage>125</spage><epage>132</epage><pages>125-132</pages><issn>0253-4886</issn><eissn>1421-9883</eissn><abstract>Background/Aims: Curative resection is still the only treatment for patients with pancreatic ductal adenocarcinoma (PDAC). However, early postoperative recurrence occurs frequently. The aim of this study was to investigate the predictors of early recurrence of PDAC. Methods: Clinical data of 172 consecutive patients with PDAC who underwent curative resection (R0) between 2000 and 2015 at Tokyo Medical University Hospital were retrospectively analyzed. Results: The median follow-up period was 18.2 months. Recurrence occurred in 96 of 172 (55.8%) patients, 27 in whom recurrence occurred within 6 months (early recurrence). Median survival time of the early recurrence group was 10.7 months. The optimal cutoff concentrations for the prediction of early recurrence were 111.3 U/ml, 3.0 ng/ml, 41 U/ml and 670 U/ml for CA19-9, carcinoembryonic antigen, SPan-1 and DUPAN-2, respectively. Multivariate analysis demonstrated that a SPan-1 concentration of >41 U/ml, having received neoadjuvant therapy and having never received adjuvant chemotherapy were significant and independent predictors of early recurrence. Conclusion: A preoperative SPan-1 concentration of >41 U/ml is a significant and independent predictor of the early recurrence of pancreatic adenocarcinoma.</abstract><cop>Basel, Switzerland</cop><pmid>27658221</pmid><doi>10.1159/000449041</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-4886 |
| ispartof | Digestive surgery, 2017-01, Vol.34 (2), p.125-132 |
| issn | 0253-4886 1421-9883 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1859725545 |
| source | Karger Journals; MEDLINE |
| subjects | Aged Antigens, Neoplasm - blood Area Under Curve CA-19-9 Antigen - blood Carcinoembryonic Antigen - blood Carcinoma, Pancreatic Ductal - blood Carcinoma, Pancreatic Ductal - secondary Carcinoma, Pancreatic Ductal - therapy Chemoradiotherapy, Adjuvant Chemotherapy, Adjuvant Disease-Free Survival Drainage Female Follow-Up Studies Humans Jaundice, Obstructive - etiology Jaundice, Obstructive - surgery Liver Neoplasms - secondary Lung Neoplasms - secondary Lymphatic Metastasis Male Neoadjuvant Therapy Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnostic imaging Original Paper Pancreatic Neoplasms - blood Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Peritoneal Neoplasms - secondary Predictive Value of Tests Preoperative Period Retrospective Studies Risk Factors ROC Curve Survival Rate Time Factors |
| title | Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T14%3A08%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20SPan-1%20Is%20a%20Significant%20Risk%20Factor%20for%20Early%20Recurrence%20of%20Pancreatic%20Cancer%20after%20Curative%20Resection&rft.jtitle=Digestive%20surgery&rft.au=Hosokawa,%20Yuichi&rft.date=2017-01-01&rft.volume=34&rft.issue=2&rft.spage=125&rft.epage=132&rft.pages=125-132&rft.issn=0253-4886&rft.eissn=1421-9883&rft_id=info:doi/10.1159/000449041&rft_dat=%3Cproquest_cross%3E1859725545%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1859725545&rft_id=info:pmid/27658221&rfr_iscdi=true |